Carballo, J. J.
Llorente, C.
Kehrmann, L.
Flamarique, I.
Zuddas, A.
Purper-Ouakil, D.
Hoekstra, P. J.
Coghill, D.
Schulze, U. M. E.
Dittmann, R. W.
Buitelaar, J. K.
Castro-Fornieles, J.
Lievesley, K.
Santosh, Paramala http://orcid.org/0000-0003-4830-5893
Arango, C.
Sutcliffe, Alastair
Curran, Sarah
Selema, Laura
Flanagan, Robert
Craig, Ian
Parnell, Nathan
Yeboah, Keren
Sala, Regina
Singh, Jatinder
Fiori, Federico
Pupier, Florence
Vinkenvleugel, Loes
Glennon, Jeffrey
Bakker, Mireille
Drent, Cora
Bloem, Elly
Steenhuis, Mark-Peter
Berg, Ruth
Häge, Alexander
Dau, Mahmud Ben
Mechler, Konstantin
Rauscher, Sylke
Aslan, Sonja
Schlanser, Simon
Keller, Ferdinand
Schneider, Alexander
Plener, Paul
Fegert, Jörg M.
Paton, Jacqui
Macey, Murray
Iessa, Noha
Alfred, Kolozsvari
Helen, Furse
Nick, Penkov
Baillon, Claire
Peyre, Hugo
Cohen, David
Bonnot, Olivier
Brunelle, Julie
Franc, Nathalie
Raysse, Pierre
Humbertclaude, Véronique
Rodriguez-Quiroga, Alberto
Díaz-Caneja, Covadonga Martínez
Espliego, Ana
Merchán, Jessica
Tapia, Cecilia
Baeza, Immaculada
Romero, Soledad
La Fuente, Amalia
Ortiz, Ana
Pintor, Manuela
Ligas, Franca
Cera, Francesca Micol
Frongia, Roberta
Falissard, Bruno
Schwalber, Ameli
Dittrich, Juliane
Wohner, Andrea
Zimmermann, Katrin
Schwalber, Andrea
Aitchison, Katherine
,
Funding for this research was provided by:
Instituto de Salud Carlos III ((S2010/BMD-2422 AGES))
Fundación Alicia Koplowitz
Fundación Mutua Madrile?a
Seventh Framework Programme (261411)
Article History
Received: 19 September 2018
Accepted: 20 December 2018
First Online: 25 January 2019
Compliance with ethical standards
:
: Professor Paramala Santosh, is the CEO, Director and stockholder in HealthTracker Ltd. Dr. K. Lievesley is a Project Manager employed at HealthTracker Ltd. Dr. Dittmann has received compensation for serving as consultant or speaker, or he or the institution he works for have received research support or royalties from the organizations or companies indicated: EU (FP7 Programme), US National Institute of Mental Health (NIMH), German Federal Ministry of Health/Regulatory Agency (BMG/BfArM), German Federal Ministry of Education and Research (BMBF), German Research Foundation (DFG), Volkswagen Foundation; Boehringer Ingelheim, Ferring, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Servier, Shire, Sunovion/Takeda and Theravance. Dr. Dittmann owns Eli Lilly stock. Dr. Zuddas has been a consultant to or has received honoraria or grants from EU (FP7 Programme), Angelini, Lundbeck, Janssen, Roche, Servier, Shire, Takeda, Vifor. Prof. Coghill reports grants and personal fees from Shire, personal fees from Janssen-Cilag, personal fees from Lilly, grants and personal fees from Vifor, personal fees from Novartis, personal fees from Flynn Pharma, personal fees from Medice, personal fees from Oxford University Press, outside the submitted work. Dr. Arango has been a consultant to or has received honoraria or grants from Acadia, Abbot, AMGEN, AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Lundbeck, Merck, Otsuka, Pfizer, Roche, Servier, Sumitomo-Dainippon Pharma, Shire, Takeda, Teva and Schering Plough. Dr Purper-Ouakil has been consultant for Shire, Boiron, Mensia and has received honoraria or travel grants from Shire, Otsuka, Medice, Jannssen-Cilag, Ardix. None of the other authors have any conflicts of interest or disclosures to declare. Part of this data has been included in an FP7 STOP Report to the European Union.
: Informed consent was obtained from all study participants.
: The study was approved by the Research Ethic Committees (RECs)/Institutional Review Boards (IRBs) of all participating centres.